businesspress24.com - Insys Therapeutics to Report Second Quarter 2015 Results
 

Insys Therapeutics to Report Second Quarter 2015 Results

ID: 1374085

(firmenpresse) - PHOENIX, AZ -- (Marketwired) -- 07/23/15 -- Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the Company will release its financial results for the second quarter 2015 on Thursday, August 6, 2015, before the U.S. financial markets open.

Following the release of the financial results, Michael L. Babich, President and Chief Executive Officer, and Darryl S. Baker, Chief Financial Officer, will host a conference call as follows:





A replay of the conference call will be available for two weeks after the call''s completion by dialing (800) 633-8284 (U.S.) or (402) 977-9140 (International). The conference ID for the replay is 21772681. The archived webcast will be available for 30 days via the aforementioned URL.

Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets two products: Subsys®, which is sublingual Fentanyl spray for breakthrough cancer pain, and a generic version of Dronabinol (THC) capsules. The Company''s recently submitted a New Drug Application to the U.S. Food and Drug Administration for Dronabinol Oral Solution, a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is developing a pipeline of sublingual sprays, as well as pharmaceutical cannabidiol.

Subsys® is a registered trademark of Insys Therapeutics, Inc.






Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Theravance to Report Second Quarter 2015 Financial Results on July 29, 2015
Shenzhen Hepalink Pharmaceutical Co., Ltd. Announces Investment in Resverlogix Corp.
Bereitgestellt von Benutzer: Marketwired
Datum: 23.07.2015 - 05:00 Uhr
Sprache: Deutsch
News-ID 1374085
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

PHOENIX, AZ


Phone:

Kategorie:

Drugs


Anmerkungen:


Diese Pressemitteilung wurde bisher 225 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Insys Therapeutics to Report Second Quarter 2015 Results
"
steht unter der journalistisch-redaktionellen Verantwortung von

Insys Therapeutics (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Insys Therapeutics



 

Who is online

All members: 10 562
Register today: 1
Register yesterday: 2
Members online: 0
Guests online: 63


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.